AEGR-733 Mesylate
Lomitapide Mesylate
CAS: 202914-84-9
Molecular Formula: C40H41F6N3O5S
AEGR-733 Mesylate - Names and Identifiers
| Name | Lomitapide Mesylate |
| Synonyms | BMS 201038-04 AEGR733 Mesylate AEGR-733 Mesylate AEGR 733 Mesylate BMS201038 Mesylate BMS 201038 Mesylate LoMitapide Mesylate Lomitapide Mesylate BMS 201038 methanesulfonic acid salt 9H-Fluorene-9-carboxamide, N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]car bonyl]amino]-1-piperidinyl]butyl]-, methanesulfonate |
| CAS | 202914-84-9 |
AEGR-733 Mesylate - Physico-chemical Properties
| Molecular Formula | C40H41F6N3O5S |
| Molar Mass | 789.8260592 |
| Solubility | 10 mM in DMSO |
| Storage Condition | Inert atmosphere,Room Temperature |
| Use | Lomitapide is a MTP inhibitor. Lomitapid is a novel agent for the treatment of homozygous familial hypercholesterolemia. Lomitapide is an orally active inhibitor of microsomal triglyceride transfer protein that is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available for the reduction of LDL-C, total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol in adult patients with HoFH. |
| Target | MTP |
AEGR-733 Mesylate - Reference
| Reference Show more | 1: Marbach JA, Thapa J, Goldenberg E, Duffy D. Pharmacogenetics in the Development of Lipid Lowering Medications: Lomitapide & Mipomersen in Clinical Practice. Del Med J. 2015 Aug;87(8):238-43. PubMed PMID: 26402926. 2: Roeters van Lennep J, Averna M, Alonso R. Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide. J Clin Lipidol. 2015 Jul-Aug;9(4):607-17. doi: 10.1016/j.jacl.2015.05.001. Epub 2015 May 14. PubMed PMID: 26228681. 3: Patel G, King A, Dutta S, Korb S, Wade JR, Foulds P, Sumeray M. Evaluation of the effects of the weak CYP3A inhibitors atorvastatin and ethinyl estradiol/norgestimate on lomitapide pharmacokinetics in healthy subjects. J Clin Pharmacol. 2015 Jun 26. doi: 10.1002/jcph.581. [Epub ahead of print] PubMed PMID: 26120010. 4: Gouni-Berthold I, Berthold HK. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia. Atheroscler Suppl. 2015 May;18:28-34. doi: 10.1016/j.atherosclerosissup.2015.02.005. PubMed PMID: 25936301. 5: Stefanutti C, Blom DJ, Averna MR, Meagher EA, Theron Hd, Marais AD, Hegele RA, Sirtori CR, Shah PK, Gaudet D, Vigna GB, Sachais BS, Di Giacomo S, du Plessis AM, Bloedon LT, Balser J, Rader DJ, Cuchel M; Phase 3 HoFH Lomitapide Study Investigators. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial. Atheros |
AEGR-733 Mesylate - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 1.266 ml | 6.331 ml | 12.661 ml |
| 5 mM | 0.253 ml | 1.266 ml | 2.532 ml |
| 10 mM | 0.127 ml | 0.633 ml | 1.266 ml |
| 5 mM | 0.025 ml | 0.127 ml | 0.253 ml |
Last Update：2024-01-02 23:10:35
Supplier List
Product Name: Lomitapide (mesylate) Visit Supplier Webpage Request for quotation
CAS: 202914-84-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 202914-84-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: Lomitapide (mesylate) Visit Supplier Webpage Request for quotation
CAS: 202914-84-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
CAS: 202914-84-9
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History